853401-03-3Relevant articles and documents
GPR120 RECEPTOR AGONISTS AND USES THEREOF
-
Page/Page column 105-106, (2012/01/06)
GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
GPR120 RECEPTOR AGONISTS AND USES THEREOF
-
Page/Page column 80-81, (2010/08/04)
GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective αvβ3 inhibitor: Design, synthesis, and optimization
Nagarajan, Srinivasan R.,Lu, Hwang-Fun,Gasiecki, Alan F.,Khanna, Ish K.,Parikh, Mihir D.,Desai, Bipinchandra N.,Rogers, Thomas E.,Clare, Michael,Chen, Barbara B.,Russell, Mark A.,Keene, Jeffery L.,Duffin, Tiffany,Engleman, V. Wayne,Finn, Mary B.,Freeman, Sandra K.,Klover, Jon A.,Nickols, G. Alan,Nickols, Maureen A.,Shannon, Kristen E.,Steininger, Christina A.,Westlin, William F.,Westlin, Marisa M.,Williams, Melanie L.
, p. 3390 - 3412 (2008/02/08)
The integrin αvβ3 is expressed in a number of cell types and is thought to play a major role in several pathological conditions. Various small molecules that inhibit the integrin have been shown to suppress tumor growth and retinal a
Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
-
, (2008/06/13)
The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.
Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
-
Page 50, (2010/02/07)
The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.
